当前位置： SCI文献检索 > ANTIVIRAL THERAPY期刊下所有文献 > Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118).

Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118).

Abstract：

BACKGROUND:Amdoxovir (2,6-diaminopurine dioxolane; DAPD) is a nucleoside reverse transcriptase inhibitor (NRTI) of human immunodeficiency virus-1 (HIV-1) with activity against wild-type and NRTI-resistant viruses. METHODS:ACTG A5118 assessed the antiretroviral activity and safety of DAPD (300 mg orally, twice daily) versus placebo in combination with enfuvirtide (ENF) plus an optimized background (OB) regimen in subjects with failure of two or more antiretroviral (ARV) regimens. The primary endpoints for comparison were time-averaged area under the curve minus baseline (AAUCMB) of plasma HIV-1 RNA concentration at 24 weeks and time to first serious (DAIDS toxicity table Grade > or = 3) adverse event (AE). An unplanned interim review recommended closing enrollment because the study was unlikely to demonstrate a difference between arms. The 18 subjects on study, nine in each arm, were unblinded and allowed to continue study treatment through 48 weeks. RESULTS:Intention-to-treat analysis showed the median AAUCMB was -0.9 log10 copies/mL (95% CI = -2.2, -.0.1) in the DAPD arm and -0.9 log10 copies/ml (95% CI = -1.1, -0.1) in the placebo arm (P = 0.69). Median CD4+ T-cell increase was 79 cells/mm3 (95% CI =1, 115) in the DAPD arm and 60 (95% CI =1, 101) in the placebo arm (P = 0.45). Time to first serious AE did not differ between arms (P = 0.91). Mild decreases of creatinine clearance were observed with similar frequency between arms; no subject developed lens opacities. CONCLUSIONS:Addition of DAPD to ENF plus OB in advanced subjects with highly resistant virus appeared safe, but did not add statistically significant antiretroviral activity at 24 weeks in this small study.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Gripshover BM,Ribaudo H,Santana J,Gerber JG,Campbell TB,Hogg E,Jarocki B,Hammer SM,Kuritzkes DR,A5118 Team.

subject

Has Abstract

pub_date

2006-01-01 00:00:00

pages

619-23

issue

5

eissn

1359-6535

issn

2040-2058

journal_volume

11

pub_type

杂志文章,多中心研究,随机对照试验

相关文献

ANTIVIRAL THERAPY文献大全
  • On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy.

    abstract：BACKGROUND:Serum HBV RNA is detectable during nucleoside/nucleotide analogue therapy as a result of unaffected RNA replicative intermediates or interrupted reverse transcription. We studied the predictive value of serum HBV RNA for initial virological response during nucleoside analogue therapy. METHODS:Serum HBV RNA ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2777

    authors： Huang YW,Takahashi S,Tsuge M,Chen CL,Wang TC,Abe H,Hu JT,Chen DS,Yang SS,Chayama K,Kao JH

    更新日期：2015-01-01 00:00:00

  • Targeting human papillomavirus genome replication for antiviral drug discovery.

    abstract：:Human papillomavirus (HPV) infections are a major human health problem; they are the cause of recurrent benign warts and of several cancers of the anogenital tract and head and neck region. Although there are two prophylactic HPV vaccines that could, if used universally, prevent as many as two-thirds of HPV-induced ca...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2612

    authors： Archambault J,Melendy T

    更新日期：2013-01-01 00:00:00

  • Stability of liver fibrosis among HCV-infected injection drug users.

    abstract：BACKGROUND:There are few published data characterizing patterns of liver stiffness measurements (LSMs) among HCV-infected persons and their potential impact on clinical decisions (for example, deferring treatment and hepatocellular carcinoma surveillance). METHODS:A total of 591 HCV-infected injection drug users in a ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2085

    authors： Mehta SH,Kirk GD,Astemborski J,Sulkowski MS,Afdhal NH,Thomas DL

    更新日期：2012-01-01 00:00:00

  • Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.

    abstract：BACKGROUND:This study aimed to examine the evolution of genotypic drug resistance prevalence in treatment-failing patients in the multicentre, Italian, Antiretroviral Resistance Cohort Analysis (ARCA). METHODS:Patients with a drug resistance genotype test performed between 1999 and 2006 at failure of a combination ant...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：

    authors： Di Giambenedetto S,Zazzi M,Corsi P,Gonnelli A,Di Pietro M,Giacometti A,Almi P,Trezzi M,Boeri E,Gianotti N,Menzo S,Del Gobbo R,Francisci D,Nerli A,Galli L,De Luca A,Antiretroviral Resistance Cohort Analysis Study Group.

    更新日期：2009-01-01 00:00:00

  • Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy.

    abstract：:We assessed the prevalence and clinical impact of insertions within the HIV-1 p6Gag proline-rich (PTAP) region on initial antiretroviral therapy response in 461 HIV-infected, drug-naive individuals initiating therapy in British Columbia, Canada between June 1996 and August 1998. HIV p6Gag insertions were detected by n...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Brumme ZL,Chan KJ,Dong WW,Wynhoven B,Mo T,Hogg RS,Montaner JS,O'Shaughnessy MV,Harrigan PR

    更新日期：2003-04-01 00:00:00

  • In vitro inhibition of HIV-1 by Met-SDF-1beta alone or in combination with antiretroviral drugs.

    abstract：:Compounds that can block the CXCR4 chemokine receptor are a promising new class of antiretroviral agents. In these experiments we studied the effect of a modified form of the native stromal cell-derived factor-1 (SDF-1), Met-SDF-1beta. The in vitro susceptibility of two different CXCR4-tropic HIV-1 strains was determi...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Rusconi S,Merrill DP,La Seta Catamancio S,Citterio P,Bulgheroni E,Croce F,Chou TC,Yang OO,Herrmann SH,Galli M,Hirsch MS

    更新日期：2000-09-01 00:00:00

  • MicroRNAs: role and therapeutic targets in viral hepatitis.

    abstract：:MicroRNAs regulate gene expression by binding to the 3'-untranslated region (UTR) of target messenger RNAs (mRNAs). The importance of microRNAs has been shown for several liver diseases, for example, viral hepatitis. MicroRNA-122 is highly abundant in the liver and is involved in the regulation of lipid metabolism. Mi...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2766

    authors： van der Ree MH,de Bruijne J,Kootstra NA,Jansen PL,Reesink HW

    更新日期：2014-01-01 00:00:00

  • Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy.

    abstract：BACKGROUND:Lamivudine is widely used in patients with chronic hepatitis B virus (HBV) infection. In cirrhotic patients, long-term lamivudine therapy significantly reduced the risk of hepatocellular carcinoma (HCC). However, in a small but substantial portion of patients, HCC still developed despite lamivudine therapy. ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Lai MW,Huang SF,Hsu CW,Chang MH,Liaw YF,Yeh CT

    更新日期：2009-01-01 00:00:00

  • NS3 genetic variability in HCV genotype-1b isolates from liver specimens and blood samples of treatment-naive patients with chronic hepatitis C.

    abstract：BACKGROUND:Two distinct inhibitors of the HCV protease have been approved for the treatment of patients infected with HCV genotype-1. These drugs are highly efficient in suppressing HCV replication; however, their use is limited by the emergence of viral mutants resistant to them after a very short time of treatment. B...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2326

    authors： Maimone S,Musolino C,Squadrito G,Raffa G,Pollicino T,Raimondo G

    更新日期：2013-01-01 00:00:00

  • Key data from the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV.

    abstract：:The effectiveness of current antiretroviral therapies has led to more patients receiving long-term therapy, and increasing numbers of older patients. The complex interactions between HIV infection, ageing, comorbid conditions and drug-related toxicities, and their combined effects on patient health and quality of life...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1470

    authors： Boehme RE,Cameron S

    更新日期：2009-01-01 00:00:00

  • HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?

    abstract：BACKGROUND:Clinical utilization of genotype resistance testing is evolving. We examined the extent to which HIV care providers requesting genotype resistance tests used the information appropriately and the impact of inappropriate utilization. METHODS:Data from a prospective cohort of HIV-infected patients (the HIV Ou...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Uy J,Brooks JT,Baker R,Hoffman M,Moorman A,Novak R,HOPS Investigators.

    更新日期：2007-01-01 00:00:00

  • Effect of long-term lamivudine in chronic hepatitis B virus-infected children.

    abstract：OBJECTIVE:To evaluate, retrospectively, biochemical, serological and histological responses in chronic hepatitis B (CHB)-infected children who received combination therapy and continued with prolonged treatment with lamivudine (3TC). PATIENTS AND METHODS:CHB infection was defined as the presence of hepatitis B surface...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章

    doi：

    authors： Ozgenç F,Arikan C,Sertoz RY,Nart D,Aydogdu S,Yagci RV

    更新日期：2004-10-01 00:00:00

  • The pathogenesis of liver disease in the setting of HIV-hepatitis B virus coinfection.

    abstract：:There are many potential reasons for increased liver-related mortality in HIV-hepatitis B virus (HBV) coinfection compared with either infection alone. HIV infects multiple cells in the liver and might potentially alter the life cycle of HBV, although evidence to date is limited. Unique mutations in HBV have been defi...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Iser DM,Lewin SR

    更新日期：2009-01-01 00:00:00

  • Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy.

    abstract：OBJECTIVE:To assess the baseline factors associated with haematological toxicity that lead to ribavirin or pegylated interferon (peginterferon) dosage reductions in hepatitis C and human immunodeficiency virus (HCV/HIV)-coinfected patients. DESIGN:Multicentre, prospective, observational study. SETTING:Eleven hospital...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,多中心研究

    doi：

    authors： Fuster D,Huertas JA,Gómez G,Solà R,González García J,Vilaró J,Pedrol E,Force L,Tor J,Sirera G,Videla S,Planas R,Clotet B,Tural C,PEG-TOX Research Group.

    更新日期：2005-01-01 00:00:00

  • Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation.

    abstract：BACKGROUND:HDV infection is a cause of severe liver disease. Diagnosis and monitoring of HDV RNA are important to patient management. Since 2012, a WHO standard for HDV RNA quantification has been available; however, the impact of RNA extraction methods on HDV viral load quantification has never been evaluated. METHOD...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3281

    authors： Bremer B,Anastasiou OE,Ciesek S,Wedemeyer H

    更新日期：2019-01-01 00:00:00

  • In combination, nucleoside reverse transcriptase inhibitors have significant effects on 3T3-L1 adipocyte lipid accumulation and survival.

    abstract：:The use of nucleoside reverse transcriptase inhibitors (NRTIs) for the treatment of HIV infection is clearly linked to the development of subcutaneous fat atrophy. Until recently, however, in vitro studies of adipocytes have shown no or only modest and inconsistent effects of these agents on adipocyte biology. This is...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Kosmiski LA,Miller HL,Klemm DJ

    更新日期：2006-01-01 00:00:00

  • Body image is a major determinant of sexual dysfunction in stable HIV-infected women.

    abstract：BACKGROUND:Prevalence and factors associated with sexual dysfunction in HIV-positive women are poorly known. METHODS:This was a cross-sectional study in a cohort of HIV-infected women. Clinically stable women were invited to participate in a female sexual dysfunction (FSD) evaluation with Female Sexual Function Index ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Luzi K,Guaraldi G,Murri R,De Paola M,Orlando G,Squillace N,Esposito R,Rochira V,Zirilli L,Martinez E

    更新日期：2009-01-01 00:00:00

  • Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.

    abstract：BACKGROUND:The aim of this study was to assess the long-term efficacy and safety of first-line treatment with once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (NRTIs). METHODS:A total of 272 antiretroviral-naive patients with a CD4+ T-cell count of 200-350 cells/mm3 were treated wit...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：

    authors： Ananworanich J,Gayet-Ageron A,Ruxrungtham K,Chetchotisakd P,Prasithsirikul W,Kiertiburanakul S,Munsakul W,Raksakulkarn P,Tansuphasawadikul S,LeBraz M,Jupimai T,Ubolyam S,Schutz M,Hirschel B,Staccato Thailand Study Group.

    更新日期：2008-01-01 00:00:00

  • Experience with nevirapine in previously treated HIV-1-infected individuals.

    abstract：OBJECTIVE:To assess the tolerability, virological, immunological and clinical effects of nevirapine in the setting of a compassionate use programme in pretreated HIV-infected individuals. DESIGN:Retrospective observational cohort-study in 13 HIV-outpatient clinics in The Netherlands. METHODS: MAIN OUTCOME MEASURES:p...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Wit FW,Dutch HIV-treating physicians.

    更新日期：2000-12-01 00:00:00

  • Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes.

    abstract：BACKGROUND:Unique serum anti-E1E2 antibodies were shown to be associated with spontaneous recovery or predictive of sustained virological response (SVR) in patients with chronic hepatitis C receiving pegylated interferon/ribavirin (PEG-IFN/RBV) therapy. The objectives were to establish the relationship between pretreat...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2671

    authors： Arnaud C,Pradat P,Spaziante M,Berthillon P,Maynard M,Taliani G,Chemin I,Trépo C,Petit MA

    更新日期：2013-01-01 00:00:00

  • Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy.

    abstract：:The standard treatment of HCV infection with pegylated interferon-alpha2a or -alpha2b and ribavirin is effective in <50% of HCV genotype-1-infected patients. To improve this figure, it might be desirable to obtain optimal plasma concentrations of the drug by increasing the dose. Unfortunately, there is great interpati...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP1609

    authors： Brochot E,Castelain S,Duverlie G,Capron D,Nguyen-Khac E,François C

    更新日期：2010-01-01 00:00:00

  • Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity.

    abstract：BACKGROUND:Antiviral and immune-modulating properties of low-molecular-weight heparin (LMWH) against coronaviridae have been reported by in vitro studies, but no in vivo evidence is yet available. We sought to know whether the timing of prophylactic doses of LMWH during the course of COVID-19 may affect the time to SAR...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3377

    authors： Trunfio M,Salvador E,Gaviraghi A,Audagnotto S,Marinaro L,Motta I,Casciaro R,Ghisetti V,Fava C,Bonora S,Di Perri G,Calcagno A,e-COVID Study Group.

    更新日期：2021-01-18 00:00:00

  • Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

    abstract：OBJECTIVE:To identify predictors of the virological response to antiretroviral therapy in patients in whom initial therapy has failed. METHODS:The Narval trial was designed to compare phenotyping, genotyping and standard of care for the choice of antiretroviral therapy in patients in whom a protease inhibitor (PI)-con...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：

    authors： Vray M,Meynard JL,Dalban C,Morand-Joubert L,Clavel F,Brun-Vézinet F,Peytavin G,Costagliola D,Girard PM,Narval Trial Group.

    更新日期：2003-10-01 00:00:00

  • Therapeutic drug monitoring of antiretroviral drugs at home using dried blood spots: a proof-of-concept study.

    abstract：BACKGROUND:In HIV-infected patients, therapeutic drug monitoring (TDM) of antiretroviral drugs is recommended in special populations and in specific situations to optimize therapy. Currently, TDM is performed via measurement of drug plasma concentrations; however, dried blood spots (DBS) may offer a patient friendly an...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2501

    authors： Kromdijk W,Mulder JW,Smit PM,Ter Heine R,Beijnen JH,Huitema AD

    更新日期：2013-01-01 00:00:00

  • Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.

    abstract：BACKGROUND:Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), was approved for HIV-1 infected, antiretroviral treatment-naive adults based on data from two Phase III trials. In the screening population, the prevalence of 49 NNRTI resistance-associated mutations (RAMs) and the impact of allowed...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,随机对照试验

    doi：10.3851/IMP2358

    authors： Vingerhoets J,Rimsky L,Van Eygen V,Nijs S,Vanveggel S,Boven K,Picchio G

    更新日期：2013-01-01 00:00:00

  • Increased CD34+/KDR+ cells are not associated with carotid artery intima-media thickness progression in chronic HIV-positive subjects.

    abstract：BACKGROUND:Endothelial progenitor cells (EPCs) are involved in the endothelium repair. Low circulating EPC levels are predictive of cardiovascular events in HIV-negative subjects. The impact of HIV infection on EPCs, and the role of EPCs in HIV-associated cardiovascular disease, is not known. We hypothesized that circu...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2013

    authors： Papasavvas E,Hsue P,Reynolds G,Pistilli M,Hancock A,Martin JN,Deeks SG,Montaner LJ

    更新日期：2012-01-01 00:00:00

  • 3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir.

    abstract：BACKGROUND:Few data are available about efficacy and durability of simplification from multi-tablet antiretroviral regimens to co-formulated efavirenz (EFV)/emtricitabine (FTC)/tenofovir (TDF) versus rilpivirine (RPV)/FTC/TDF in virologically suppressed HIV-1-infected patients. METHODS:We retrospectively analysed HIV-...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：10.3851/IMP3188

    authors： Gagliardini R,Bandera A,Zaccarelli M,Sterrantino G,Latini A,D'Avino A,Lapadula G,Antinori A,Cauda R,De Luca A,Gori A,Di Giambenedetto S,Fabbiani M

    更新日期：2018-01-01 00:00:00

  • The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study.

    abstract：BACKGROUND:Nucleoside (or nucleotide) reverse transcriptase inhibitors (NRTIs) cause side effects in some patients, prompting the use of either partly or fully NRTI-sparing regimens. METHODS:We used data from the Swiss HIV Cohort Study to estimate the effectiveness of two new dolutegravir dual regimens relative to the...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3310

    authors： Young J,Scherrer AU,Calmy A,Tarr PE,Bernasconi E,Cavassini M,Hachfeld A,Vernazza P,Günthard HF,Bucher HC,Swiss HIV Cohort Study.

    更新日期：2019-01-01 00:00:00

  • Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.

    abstract：BACKGROUND:Suboptimal doses of ribavirin have been suggested to explain the diminished efficacy of pegylated interferon (PEG-IFN) plus ribavirin in hepatitis C virus (HCV)-HIV-coinfected patients. METHODS:A cohort of 104 coinfected patients and an age-, sex- and genotype-matched cohort of HCV-monoinfected patients (n ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Tural C,Galeras JA,Planas R,Coll S,Sirera G,Giménez D,Salas A,Rey-Joly C,Cirera I,Márquez C,Tor J,Videla S,García-Retortillo M,Clotet B,Solà R

    更新日期：2008-01-01 00:00:00

  • Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.

    abstract：BACKGROUND:The objective of this study was to compare indinavir peak plasma (Cmax) values after administration of indinavir/ritonavir 800/100 mg on an empty stomach or with food. High indinavir Cmax values have been associated with indinavir-related nephrotoxicity. METHODS:This was an open-label, randomized, two-treat...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：

    authors： Aarnoutse RE,Wasmuth JC,Fätkenheuer G,Schneider K,Schmitz K,de Boo TM,Reiss P,Hekster YA,Burger DM,Rockstroh JK

    更新日期：2003-08-01 00:00:00